Trial Radar IA | ||
|---|---|---|
Lo studio clinico NCT06067828 (ATHLOS) per Malattia polmonare ostruttiva cronica è in arruolamento. Consulti la vista a schede del Radar degli Studi Clinici e gli strumenti di scoperta IA per tutti i dettagli. Oppure, ponga pure una domanda qui. | ||
Un studio corrisponde ai criteri del filtro
Vista a schede
Torna alla ricerca
AstraZenecaA Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD). (ATHLOS)
I dettagli dello studio clinico sono disponibili principalmente in inglese. Tuttavia, Trial Radar IA può essere d'aiuto! Basta cliccare su 'Spiega lo studio' per visualizzare e discutere le informazioni sullo studio nella lingua selezionata.
La sperimentazione clinica NCT06067828 (ATHLOS) è uno studio interventistico di Fase III volto a esaminare il trattamento per Malattia polmonare ostruttiva cronica, attualmente in arruolamento. Avviato il 24 ottobre 2023, prevede di arruolare 180 partecipanti. Sotto la guida di AstraZeneca, dovrebbe concludersi entro il 30 gennaio 2026. I dati più recenti da ClinicalTrials.gov sono stati aggiornati l'ultima volta il 8 ottobre 2025.
Sommario breve
This study will investigate the effect of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) metered dose inhaler (MDI) compared with Placebo MDI, and Budesonide and Formoterol Fumarate (BFF) MDI on isotime inspiratory capacity (IC) and exercise endurance time.
Descrizione dettagliata
This is a multicenter, three-treatment, three-period, cross-over study to assess the effect of BGF MDI vs Placebo MDI and BFF MDI in participants with COPD who have exertional breathlessness despite treatment with mono or dual COPD maintenance therapy.
Eligible participants will be randomized equally (1:1:1:1:1:1) to 1 of 6 treatment sequences. The total duration of the study for each participant will be up to 14 weeks.
Titolo ufficiale
A Double-Blind, Multicentre, Randomized, Three-Period, Three-Treatment, Cross-Over Study to Evaluate the Effect of BGF MDI, BFF MDI, and Placebo MDI on Exercise Parameters in Participants With COPD (ATHLOS)
Condizioni
Malattia polmonare ostruttiva cronicaAltri ID dello studio
- ATHLOS
- D5988C00001
Numero NCT
Data di inizio (effettiva)
2023-10-24
Ultimo aggiornamento pubblicato
2025-10-08
Data di completamento (stimata)
2026-01-30
Arruolamento (previsto)
180
Tipo di studio
Interventistico
FASE
Fase III
Stato
In arruolamento
Parole chiave
Metered Dose Inhalers
Scopo principale
Trattamento
Allocazione
Randomizzato
Modello di intervento
Cross-over
Mascheramento
Doppio
Bracci / Interventi
| Gruppo/Braccio di partecipanti | Intervento/Trattamento |
|---|---|
Comparatore attivoBGF MDI Pressurized MDI fixed combination product of Budesonide 160 μg, Glycopyrronium 7.2 μg, and Formoterol Fumarate 4.8 μg per actuation. | Treatment a : Budesonide, Glycopyrronium, and Formoterol Fumarate Randomized participants will receive 2 inhalations of BGF MDI via oral inhalation twice daily (BID). |
Comparatore attivoBFF MDI Pressurized MDI fixed combination product of Budesonide 160 μg and Formoterol Fumarate 4.8 μg per actuation. | Treatment B: Budesonide and Formoterol Fumarate Randomized participants will receive 2 inhalations of BFF MDI via oral inhalation BID. |
Comparatore placeboPlacebo Placebo as pressurized inhalation suspension. | Treatment C : Placebo Randomized participants will receive 2 inhalations of placebo MDI via oral inhalation BID. |
Esito primario
Esito secondario
| Misure di esito | Descrizione della misura | Arco temporale |
|---|---|---|
Change from baseline in isotime Inspiratory capacity (IC) | To assess the effect of BGF MDI relative to Placebo MDI and BGF MDI relative to BFF MDI on dynamic hyperinflation in participants with COPD. | 2 weeks post-treatment |
| Misure di esito | Descrizione della misura | Arco temporale |
|---|---|---|
Change from baseline in constant work rate cycle ergometry endurance time | To assess the effect of BGF MDI relative to Placebo MDI, BGF MDI relative to BFF MDI and BFF MDI relative to Placebo MDI on exercise endurance time in participants with COPD. | 2 weeks post-treatment |
Change from baseline in Isotime dyspnea (NRS) | To assess the effect of BGF MDI relative to Placebo MDI, BGF MDI relative to BFF MDI and BFF MDI relative to Placebo MDI on Isotime dyspnea in participants with COPD. | 2 weeks post-treatment |
Change from baseline in functional residual capacity (FRC) | To assess the effect of BGF MDI relative to BFF MDI and BFF MDI relative to Placebo MDI on FRC in participants with COPD. | 2 weeks post-treatment |
Change from baseline in total lung capacity (TLC) | To assess the effect of BGF MDI relative to BFF MDI and BFF MDI relative to Placebo MDI on TLC in participants with COPD. | 2 weeks post-treatment |
Change from baseline in residual volume (RV) | To assess the effect of BGF MDI relative to BFF MDI and BFF MDI relative to Placebo MDI on RV in participants with COPD. | 2 weeks post-treatment |
Change from baseline in RV/TLC | To assess the effect of BGF MDI relative to BFF MDI and BFF MDI relative to Placebo MDI on RV/TLC in participants with COPD. | 2 weeks post-treatment |
Change from baseline in specific airway conductance (sGaw) | To assess the effect of BGF MDI relative to BFF MDI and BFF MDI relative to Placebo MDI on sGaw in participants with COPD. | 2 weeks post-treatment |
Change from baseline in static Inspiratory capacity (IC) | To assess the effect of BGF MDI relative to BFF MDI and BFF MDI relative to Placebo MDI on static IC in participants with COPD. | 2 weeks post-treatment |
Number of participants with serious adverse events (SAEs) and adverse event leading to discontinuation of study intervention (DAEs). | To assess the safety and tolerability of BGF MDI and BFF MDI. | 2 weeks post-treatment |
Criteri di eleggibilità
Età idonea
Adulto, Adulto anziano
Età minima
40 Years
Sessi idonei
Tutti
Participant must be male or female, 40 to 80 years of age inclusive, at the time of signing the informed consent.
Participant must have:
- a diagnosis of COPD confirmed by a post-bronchodilator Forced expiratory volume (FEV1)/ Forced vital capacity (FVC) < 0.7 at Visit 1
- a post-bronchodilator FEV1 ≥ 30% and <80% predicted normal (moderate to severe COPD) at Visit 1.
- a score of ≥ 2 on the modified Medical Research Council at Visit 1.
- pre-bronchodilator FRC of > 120% of predicted normal FRC values at Visit 1.
- a constant work rate test endurance time of 3 to 8 minutes at Visit 2.
Participant must be on a stable dose of mono-or dual inhaled maintenance COPD treatment for at least 6 weeks.
Current or former smoker with a history of ≥ 10 pack-years of tobacco smoking
Body mass index < 40 kg/m2.
Male and Female participants (not applicable for female participants with non-childbearing potential) and their partners must use an acceptable method of contraception.
- A current diagnosis of asthma, asthma- COPD-overlap, or any other chronic respiratory disease other than COPD such as alpha-1 antitrypsin deficiency, active tuberculosis, lung cancer, lung fibrosis, sarcoidosis, interstitial lung disease and pulmonary hypertension.
- Historical or current evidence of a clinically significant disease
- Participants on oxygen therapy or that desaturate significantly (<82%) during exercise.
- Participants who are enrolled or entering a pulmonary rehabilitation program during the study.
- Participants who have cancer that has not been in complete remission for at least 5 years.
- Participants with a diagnosis of narrow-angle glaucoma that has not been adequately treated and/or change in vision that may be relevant, in the opinion of the investigator.
- Participants with symptomatic prostatic hypertrophy or bladder neck obstruction/urinary retention that, in the opinion of the investigator, is clinically significant.
- Participants who have a history of hypersensitivity to β2-agonists, budesonide or any other corticosteroid components, glycopyrronium or other muscarinic anticholinergics, or any component of the MDI or dry powder inhaler.
- Participant with resting (5 minutes) oxygen saturation SaO2 in room air ≤ 85%.
- A COPD exacerbation that requires hospitalization within 12 months prior to Visit 1 or a COPD exacerbation that requires systemic corticosteroids or antibiotics within 4 months of Visit 1.
- Participants with contraindications to cardiopulmonary exercise testing (CPET).
- Participants who have had a respiratory tract infection within 8 weeks prior to Visit 1 and/or during the screening period.
- Participants with lung lobectomy, lung volume reduction or lung transplantation.
- Unable to withhold short-acting bronchodilators for 6 hours prior to lung function testing at each study visit.
- Known history of drug or alcohol abuse within 12 months.
- Any regular recreational use of marijuana in the 12 months.
AstraZeneca778 studi clinici attivi da esplorareContatti principali dello studio
Contatto: AstraZeneca Clinical Study Information Center, 1-877-240-9479, [email protected]
37 Centri dello studio in 8 paesi
California
Research Site, Los Angeles, California, 90095, United States
Non ancora in arruolamento
Research Site, Tarzana, California, 91356, United States
Non ancora in arruolamento
Research Site, Torrance, California, 90502, United States
In arruolamento
Florida
Research Site, Brooksville, Florida, 34613, United States
In arruolamento
South Carolina
Research Site, Anderson, South Carolina, 29621, United States
In arruolamento
Research Site, Greenville, South Carolina, 29615, United States
In arruolamento
Research Site, Spartanburg, South Carolina, 29303, United States
In arruolamento
Research Site, CABA, 1426, Argentina
Ritirato
Research Site, Ciudad de Buenos Aires, C1280AEB, Argentina
Ritirato
Research Site, Quilmes, B1878FNR, Argentina
Ritirato
Alberta
Research Site, Edmonton, Alberta, T6G 2B7, Canada
In arruolamento
Ontario
Research Site, Kingston, Ontario, K7L 2V7, Canada
In arruolamento
Quebec
Research Site, Sainte-Foy, Quebec, G1V 4G5, Canada
In arruolamento
Research Site, Guangzhou, 510163, China
In arruolamento
Research Site, Nanchang, 330006, China
In arruolamento
Research Site, Shenyang, 110001, China
In arruolamento
Research Site, Zhengzhou, 450000, China
In arruolamento
Research Site, Berlin, 12159, Germany
In arruolamento
Research Site, Berlin, 14050, Germany
In arruolamento
Research Site, Frankfurt, 60596, Germany
In arruolamento
Research Site, Großhansdorf, 22927, Germany
In arruolamento
Research Site, Hanover, 30449, Germany
In arruolamento
Research Site, Heidelberg, 69115, Germany
In arruolamento
Research Site, Lübeck, 23552, Germany
In arruolamento
Research Site, Mainz, 55128, Germany
In arruolamento
Research Site, Daegu, 42415, South Korea
In arruolamento
Research Site, Seoul, 02447, South Korea
In arruolamento
Research Site, Seoul, 05030, South Korea
In arruolamento
Research Site, Benalmádena, 29630, Spain
In arruolamento
Research Site, Madrid, 28007, Spain
In arruolamento
Research Site, Santiago de Compostela, 15706, Spain
Non ancora in arruolamento
Research Site, Seville, 41013, Spain
Non ancora in arruolamento
Research Site, Leeds, LS9 7TF, United Kingdom
Ritirato
Research Site, Leicester, LE1 5WW, United Kingdom
In arruolamento
Research Site, London, SW3 6HP, United Kingdom
In arruolamento
Research Site, London, W1T 6AH, United Kingdom
In arruolamento
Research Site, Manchester, M23 9GP, United Kingdom
In arruolamento